XML 63 R45.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2021 | May 31, 2021 | Dec. 31, 2021 | Jan. 01, 2021 | Jan. 03, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Research and development |  |  | $ 693,716 | $ 547,851 | $ 336,964
Collaborative Agreement With Gama Mabs Pharma S A |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Payments to acquire assets |  | $ 10,000 |  |  |
Payment upon closing of transaction |  | 4,000 |  |  |
Asset acquisition, maximum aggregate development milestone payments |  | 42,000 |  |  |
Asset acquisition, maximum aggregate regulatory milestone payments |  | $ 22,500 |  |  |
Research Collaborations, In-Licensing Arrangements and Other Business Development Activities |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Potential future development milestone payments | $ 254,300 |  | 254,300 |  |
Potential regulatory milestone payments | 426,500 |  | 426,500 |  |
Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments | 1,911,500 |  | 1,911,500 |  |
Research and development |  |  | $ 176,100 | $ 96,400 | $ 47,700
Collaboration Agreement With Iconic Therapeutics Inc |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Collaboration agreement, final payment | 55,000 |  |  |  |
Research and development | $ 55,000 |  |  |  |

X
- Definition Asset Acquisition, Maximum Aggregate Development Milestone Payments + References No definition available. + Details
Name: | exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments + References No definition available. + Details
Name: | exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Payment Upon Closing Of Transaction + References No definition available. + Details
Name: | exel_AssetAcquisitionPaymentUponClosingOfTransaction
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Final Payment + References No definition available. + Details
Name: | exel_CollaborativeArrangementRightsAndObligationsFinalPayment
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments + References No definition available. + Details
Name: | exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments + References No definition available. + Details
Name: | exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments + References No definition available. + Details
Name: | exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495 + Details
Name: | us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |